Trial Profile
Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by Thalidomide maintenance versus MP-Lenalidomide (MP-Len) follwed by maintenance with Lenalidomide
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan; Prednisone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms HOVON 87 MM/NMSG 18
- 04 Sep 2020 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 10 Dec 2019 Results (n=149) assessing genes involved in the CRBN pathway which predict the response to therapy with Immune modulating agents were presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 24 Sep 2019 This trial has been completed in Denmark